Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High Dose Chemotherapy for Relapsed Non-Hodgkin's Lymphoma
NCT00003957Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 1998
- Primary completion
- Sep 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, paclitaxel, cytarabine, mitoxantrone, etoposide and 1 more in non-Hodgkin lymphoma (NHL), sponsored by Fox Chase Cancer Center. Primary endpoint: Collection of CD34+ Cells. Started Dec 1998; status: completed.
02
Drugs
cyclophosphamidepaclitaxelcytarabinemitoxantroneetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003957.